Performance evaluation of a point-of-care whole blood viral load test (SAMBA II HIV-1 Semi-Q Whole Blood) to optimise HIV treatment

Submission date 31/08/2016	Recruitment status No longer recruiting	[X] Prospectively registered
		☐ Protocol
Registration date	Overall study status	Statistical analysis plan
02/09/2016	Completed	Results
Last Edited	Condition category	Individual participant data
25/09/2018	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Background and study aims

The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. HIV attacks and weakens the immune system, making it more difficult for a sufferer to fight infections. It is a highly contagious disease, through bodily fluids such as blood, semen and vaginal fluids. There is currently no cure for HIV, but there are a range of drug treatments that can allow people who are HIV positive to lead a long and full life. Antiretroviral therapy (ART) is the standard treatment for HIV, where at least three different antiretroviral (ARV) drugs are given at the same time. This treatment is very effective at suppressing the virus and stopping the development of the disease. When a person has been on ART, the amount of HIV present in the blood (viral load) is reduced. Routinely monitoring the viral load (VL) through regular blood testing is a vital part of this treatment strategy, as it is able to identify treatment failure so the drugs used can be changed. Current HIV VL tests are limited to centralised laboratories, as they require high organization and trained personnel. HIV patients living outside of major cities in developing countries often do not have access to VL testing. Even when VL testing is available, there are often delays in obtaining test results or loss of samples during shipment, leading to high loss to follow-up. Point-of-care VL testing (testing samples there and then) in lower healthcare facilities may overcome these limitations, improving patient outcomes and preventing spread of the disease. The aim of this study is to find out whether point-of-care HIV viral load testing with SAMBA II HIV-1 Whole Blood SemiQ is as accurate as centralised HIV viral load testing.

Who can participate? HIV positive adults

What does the study involve?

HIV positive patients who attend the clinics for routine VL monitoring are invited to provide an additional blood sample for VL testing with SAMBA II HIV-1 Whole Blood Semi-Q at the same time as they provide blood samples for their routine VL testing. The clinic processes the blood for the routine HIV VL test and informs patients of the results according to normal clinic procedures. The additional blood sample is tested with SAMBA II HIV-1 Whole Blood Semi-Q, but

patients are not given the results. The results from the two tests are then compared in order to find out whether the point-of-care testing is as accurate as the normal procedure.

What are the possible benefits and risks of participating?

There are no direct benefits or risks involved to participants taking part in this study.

Where is the study run from?

The study will be conducted in 4 countries: United Kingdom, Ukraine, Cameroon and Uganda. There will be one clinic in each of the United Kingdom (Central Middlesex Hospital, London) and Ukraine (National Medical Academy, Kiev) and up to 6 rural lower healthcare clinics in Uganda and Cameroon.

When is the study starting and how long is it expected to run for? June 2016 to August 2017

Who is funding the study? Medical Research Council (UK)

Who is the main contact? Dr Sarah Oakley-Mudge

Contact information

Type(s)

Scientific

Contact name

Dr Allyson Ritchie

Contact details

_

Cambridge United Kingdom

_

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers MRC SAMBA II WB Semi-Q

Study information

Scientific Title

Comparing a new point-of-care whole blood viral load test (SAMBA II HIV-1 Whole Blood Semi-Q) to a gold standard test in HIV positive patients in the UK, Ukraine and Africa: A diagnostic accuracy study

Study objectives

Point-of-care HIV viral load testing with SAMBA II HIV-1 Whole Blood SemiQ is concordant with Gold Standard centralised HIV viral load testing.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multi-centre non-randomised diagnostic accuracy study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

HIV

Interventions

HIV positive patients who attend the clinic for routine VL monitoring will be invited to provide an additional blood sample for VL testing with SAMBA II HIV-1 Whole Blood Semi-Q. Trained clinic staff will collect venous blood required for the routine clinic tests together with one additional blood sample (either venous or capillary). The clinic will process the blood for the routine HIV VL test and inform patients of the results according to normal clinic procedures. The additional blood sample will be tested with SAMBA II HIV-1 Whole Blood Semi-Q. Patients will not receive the results from the SAMBA II HIV-1 Whole Blood Semi-Q assay. There is no follow up for participants.

Intervention Type

Device

Primary outcome measure

Diagnostic accuracy of the SAMBA HIV-1 Whole Blood Semi-Q test determined by concordance to the Gold Standard HIV viral load test (within 0.3 log10 copies/ml).

Secondary outcome measures

Association between collected clinical covariates (age, country and gender) with the concordance between test is determined using the Wald test statistic of parameter associated with clinical covariate in logistic regression with concordance as outcome.

Overall study start date

01/06/2016

Completion date

15/10/2018

Eligibility

Key inclusion criteria

- 1. HIV sero-positive
- 2. Aged 18 years and over
- 3. Able to understand patient information sheet and consent form

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

2300

Key exclusion criteria

- 1.Below 18 years old or unable to understand forms or procedure
- 2. Pregnant women
- 3. Co-infection with active TB

Date of first enrolment


01/11/2016

Date of final enrolment

02/06/2017

Locations

Countries of recruitment



Study participating centre
Central Middlesex Hospital
Acton Lane
Park Royal
London
United Kingdom
NW10 7NS

Cameroon

Study participating centre National Academy of Postgraduate Education Ukraine 04112

Study participating centre Ministry of Health Uganda P.O. Box 7272

Study participating centre Global Health Solutions Cameroon Box Limbe L

Sponsor information

Organisation

Diagnostics for the Real World (Europe) Ltd.

Sponsor details

Suite 8
Science Village
Chesterford Research Park
Cambridge
United Kingdom
CB10 1XL

Sponsor type

Industry

ROR

https://ror.org/04e2ayg86

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal.

Intention to publish date

01/08/2018

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available